Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Dr. Gupta on the Methodologies of the PARADIGM Study in Urothelial Cancer

June 20th 2022

Shilpa Gupta, MD, discusses the methodologies utilized in the PARADIGM study in locally advanced or metastatic urothelial cancer.

Dr. Gupta on the Design of the PARADIGM Study in Urothelial Cancer

June 19th 2022

Shilpa Gupta, MD, discusses the design of the PARADIGM study in locally advanced or metastatic urothelial cancer.

Dr. Packiam on Safety of Cabazitaxel/Gemcitabine Plus Pembrolizumab in Urothelial Carcinoma

June 15th 2022

Vignesh Packiam, MD, discusses the adverse effects associated with cabazitaxel and gemcitabine with pembrolizumab in patients who are unresponsive to docetaxel with non-muscle invasive urothelial carcinoma.

Maintenance Avelumab Maintains Survival Benefit as First-Line Maintenance Across Subgroups in Advanced Urothelial Cancer

June 4th 2022

The addition of maintenance avelumab to best supportive care demonstrated improved outcomes for patients with advanced urothelial carcinoma including those who went on to receive second-line therapy.

TMB Serves as Predictive Biomarker of Toripalimab Efficacy in Urothelial Carcinoma

June 4th 2022

Tumor mutational burden served as a prognostic indicator of the efficacy of toripalimab among Chinese patients with urothelial carcinoma.

Atezolizumab Plus Cabozantinib Elicits Clinical Activity in Advanced Urothelial Cancer

June 4th 2022

Cabozantinib plus atezolizumab demonstrated promising clinical activity and a suitable safety profile as first-line therapy in patients with cisplatin- eligible and -ineligible, inoperable locally advanced or metastatic urothelial cancer and as second- or later-line therapy in those who received a prior immune checkpoint inhibitor, according to findings from the phase 1b COSMIC-021 trial.

Single-Agent Cabozantinib Stalls as Maintenance Therapy in Advanced Urothelial Cancer

June 4th 2022

Results of the ATLANTIS study do not support further investigation of cabozantinib alone as a maintenance therapy after platinum-based chemotherapy in unselected patients with advanced urothelial cancer.

Dr. Galsky on Initial Data From the CheckMate 274 Trial in Urothelial Cancer

June 1st 2022

Matthew Galsky, MD, discusses the design and findings of the phase 3 CheckMate 274 trial in urothelial cancer.

Neoadjuvant Enfortumab Vedotin May Be an Option for Cisplatin-Ineligible MIBC

May 28th 2022

Neoadjuvant administration of the antibody drug conjugate enfortumab vedotin-ejfv represents a potential future treatment option for patients with muscle invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.

Dr. Packiam the Investigation of Cabazitaxel Plus Gemcitabine with Pembrolizumab in Urothelial Carcinoma

May 25th 2022

Vignesh Packiam, MD, discusses the investigation of cabazitaxel and gemcitabine with pembrolizumab in patients who are unresponsive to docetaxel with non-muscle invasive urothelial carcinoma.

Dr. Galsky on the Rationale of the CheckMate 274 Trial in Urothelial Carcinoma

May 24th 2022

Matthew Galsky, MD, discusses the rationale of the phase 3 CheckMate 274 trial in urothelial cancer.

FDA Approval Sought for N-803 Plus BCG in BCG-Unresponsive NMIBC Carcinoma in Situ

May 23rd 2022

A biologics license application seeking the approval of N-803 in combination with Bacillus Calmette-Guérin in patients with BCG-unresponsive, non–muscle invasive bladder cancer carcinoma in situ with or without Ta or T1 disease has been submitted to the FDA.

Sacituzumab Govitecan Under Further Exploration in Metastatic Urothelial Cancer

May 19th 2022

Sacituzumab govitecan will be further evaluated in patients with locally advanced unresectable or metastatic urothelial cancer that has progressed after prior platinum or checkpoint inhibitor therapy, as a part of the phase 3 TROPiCS-04 trial.

A Widening Scope of Treatment Options Advances Care in Bladder Cancer and RCC

May 18th 2022

Mark T. Fleming, MD, reviews the use of first-line checkpoint inhibitors in bladder cancer, the efficacy of enfortumab vedotin-ejfv in urothelial cancer, and the clinical benefits of using different mechanisms of action to treat renal cell carcinoma.

Dr. Grivas on the Future of the TROPHY U-01 Regimen in Urothelial Cancer

May 17th 2022

Petros Grivas, MD, PhD, discusses the future of the phase 2 TROPHY U-01 trial regimen in metastatic urothelial cancer.

Toripalimab Produces Promising Clinical Activity in Metastatic Urothelial Cancer

May 17th 2022

The recombinant humanized anti–PD-1 monoclonal antibody toripalimab elicited an encouraging objective response rate with an acceptable toxicity profile in patients with metastatic urothelial cancer who were refractory to frontline chemotherapy.

Immunotherapy Plus Nadofaragene Firadenovec Could Display Synergistic Activity in NMIBC

May 17th 2022

Nadofaragene firadenovec combined with immune checkpoint inhibitors such as pembrolizumab may play a synergistic role in the treatment of patients with Bacillus Calmette–Guérin-unresponsive non–muscle invasive bladder cancer.

Antegrade Administration of Mitomycin Gel Provides Safe, Effective Approach in Upper Tract Urothelial Carcinoma

May 16th 2022

Data from a retrospective analysis demonstrated that mitomycin gel was safe and effective when administered using an antegrade approach in real-world populations of patients with low-grade upper tract urothelial cancer.

Neoadjuvant Tislelizumab/Nab-Paclitaxel Combo Produces Early Activity in MIBC

May 16th 2022

The combination of neoadjuvant tislelizumab and nab-paclitaxel elicited a high rate of pathologic complete response in patients with muscle-invasive bladder cancer, according to preliminary findings from the phase 2 TRUCE-01 trial.

Frontline Nivolumab/Ipilimumab Misses OS End Point in PD-L1+ Unresectable or Metastatic Urothelial Carcinoma

May 16th 2022

The combination of nivolumab plus ipilimumab was not found to significantly improve overall survival over standard-of-care chemotherapy when used in the first-line treatment of patients with unresectable or metastatic urothelial carcinoma with a PD-L1 expression of 1% or higher.